News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Bay Area's Igenica, Inc. Follows Genentech (RHHBY) Into Antibody-Linked Cancer Drugs



4/14/2014 7:10:07 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Squint a little, and it’s easy to see the first five years of Burlingame, CA-based Igenica Biotherapeutics as a speeded-up version of the evolution of biotech pioneer Genentech. Igenica’s leadership ranks are studded with Genentech alumni, including its board chair David Goeddel, a pioneer in gene expression research who was the first scientist Genentech hired. Igenica has just started its first clinical trial on an anti-cancer antibody—-following in the footsteps of Genentech, which developed groundbreaking antibody drugs such as Rituxan, a blockbuster treatment for the blood cancer non-Hodgkin’s lymphoma approved in 1997.

Help employers find you! Check out all the jobs and post your resume.



comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES